The Best GLP-1 Apps in the US: Compounded Doses, Insurance Appeals, and the HIPAA Gap

Ten GLP-1 apps scored against the same six-pillar rubric, read through the two questions that decide the American experience of this drug class: which channel you are buying through, and who is allowed to see your data once you start logging it. No paid placements, no affiliate links.

The short version

Zenday App is our top pick at 4.55/5, ahead of Shotsy (4.35) and Regimen (4.05). The medication is the engine; Zenday is the steering - it connects injection day to how you feel and what to eat, and treats side effects as the core of the product rather than a symptom list.

But American readers should weight this list differently than European ones, for two reasons that do not exist anywhere else: a large share of US patients are on compounded semaglutide or tirzepatide at non-standard doses, and none of these apps is covered by HIPAA. Both change which features actually matter. Details below.

The compounded-dose problem

Compounded GLP-1s became normal in the US in a way they never did in Europe, and the ground is now shifting under them. The FDA issued more than 55 warning letters to online sellers in September 2025 and 30 more to telehealth companies in March 2026 over marketing that implied equivalence to approved products. On 30 April 2026 it proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List - the change that would close the last broad legal pathway for compounded supply. Patient-specific 503A compounding with documented clinical need survives; high-volume telehealth shops are the target.

For app choice, this has a concrete consequence. Compounded vials come in units and concentrations that branded pens do not, so an app that only understands a 0.25-2.4 mg pen ladder is useless to a large slice of American users. Shotsy handles compounded semaglutide and tirzepatide with custom doses; Regimen models over 150 compounds and includes reconstitution math outright. If your vial did not come from a pharmacy counter in a branded box, start with those two and check the dose entry screen before you commit a year of logging to it.

What you will actually pay - and why the app is a rounding error

The US is the only market on our list where the sticker price is not the main question. The channel is.

Manufacturer self-pay has become the default for the uninsured: as of mid-2026, LillyDirect sells Zepbound vials at $299 a month (2.5 mg), $399 (5 mg), and $449 for 7.5-15 mg, while NovoCare offers all standard Wegovy doses at $349 a month, the 7.2 mg HD dose at $399, and the first two starter fills at $199 each.

Commercial insurance that covers the drug plus a manufacturer savings card can land you near $25 a fill - a twentyfold difference from self-pay, driven entirely by paperwork. Medicare still does not cover these drugs for weight loss alone, though the CMS Medicare GLP-1 Bridge program from 1 July 2026 extends Part D coverage to the KwikPen formulation for obesity-only diagnoses with a $50 monthly copay cap through 31 December 2027. Medicaid varies by state, sometimes drastically.

Whichever lane you are in, the arithmetic on apps is the same: a subscription is a rounding error against $349 a month, and prior-authorization appeals are won with documentation. Which brings us to the feature that matters most in the American system.

The feature that earns its place in the US: the clinician export

In a system that runs on prior authorization, step therapy, and appeals, a dated record of doses, side effects, and weight is not a nice-to-have - it is evidence. Shotsy’s PDF export is built exactly for that handoff, and it is the single strongest argument for putting it above better-scoring apps in an American context. Phaze also exports reports; MeAgain, despite the widest daily logging in the field, does not, which costs it more here than it does in Europe.

HIPAA does not cover these apps

This is the American privacy fact almost nobody states plainly. HIPAA governs providers, plans, and their business associates - not a direct-to-consumer app you downloaded yourself. The floor for these products is the FTC Health Breach Notification Rule, updated in 2024 to spell out that health apps drawing data from multiple sources are covered, and that an unauthorized disclosure counts as a breach even without any hacking involved. The FTC has enforced it: GoodRx was the first such action, in February 2023, over sharing health data with advertisers.

State law then layers on top - most consequentially Washington’s My Health My Data Act, which reaches consumer health data no federal rule touches. It is telling that Phaze names HIPAA, CCPA, and My Health My Data compliance explicitly and keeps doses, injection sites, and side effects encrypted on the device with no cloud storage at all. GlucoPal takes the blunter route: no account, backups to your own iCloud. Zenday solves a different piece of it - its web version leaves no App Store trail and no icon on your home screen, which matters if the phone gets handed around.

At the far end sits MyFitnessPal, with a decade of advertising integrations and the widest data surface on this list. It is a fine food diary. Consider what else you are willing to put in it.

The rest of the ranking

2. Shotsy - 4.35/5. The most polished tracker in the category and the one most Americans should start with: one-tap dose logging, automatic injection-site rotation, side-effect severity tied to the dose timeline, estimated medication-level curves from published pharmacokinetic data, compounded-dose support, and the clinician PDF export. The catch: the medication-level curve sits behind Shotsy+, and its data architecture is thinly documented.

3. Regimen - 4.05/5. The technical pick and the best value in the field: real-time pharmacokinetic modelling across 150+ compounds including retatrutide, 50+ check-in markers, built-in reconstitution calculators, and the medication-level curve given away rather than paywalled. $4.99 a month only if you track a second compound. The catch: compound breadth invites off-label use, and the track record is short.

4. MeAgain and 5. Phaze, tied at 4.00. MeAgain wins on functionality and track record - the widest daily logging here, roughly 500,000 users - but ships no clinician export. Phaze wins on privacy by a distance and is the only app naming its US compliance regimes, but its 32-rating review base is not yet a reliability record. In an insurance-driven system, that missing export is the more expensive gap.

Behind them: GlucoPal (3.80, iPhone-only, no account required), Glapp (3.75, free outright), Pep (3.65), MyFitnessPal (3.20, the generalist), and DoneDose (3.00, injection-site mapping only). The full pillar-by-pillar scoring is on our GLP-1 app ranking.

A word on telehealth platforms

In the US more than anywhere, the line between a tracker and a seller is blurred on purpose. Everything on this page is a self-tracking tool: you bring the prescription, the app helps you run it. Telehealth platforms prescribe, supply, and bill - and, as the FDA warning letters show, some of them market compounded product in ways regulators consider misleading. Apps that drift toward a prescribing posture are capped at 1/5 on our Safety pillar no matter how good the tracking is.

How we score

An anchored 1-5 rubric: Functionality (30%), Privacy (25%), Reliability (20%), UX (15%), Honest pricing (5%), Safety content (5%) - applied identically to every app, with the weights published before the results so you can redo the arithmetic. Details on the methodology page. Worth repeating because this category is unusually bad for it: most "best GLP-1 app" roundups are published by the apps themselves, each ranking itself first. We take no paid placements, no developer promo codes, and fund the work from our own budget. If you also work with research peptides, the peptide app ranking uses the same six pillars.